Design and in vitro/in vivo evaluation of novel nicorandil extended release matrix tablets based on hydrophilic interpolymer complexes and a hydrophobic waxy polymer

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 69, Issue 3, 2008, Pages 1019-1028

  Abdelbary, Ghada Ahmed ^a   Tadros, Mina Ibrahim ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Alginate; Chitosan; Hyaluronic acid sodium salt; Imwitor 900 K; Interpolymer complex; Matrix tablet; Nicorandil; Pectin

Indexed keywords

ALGINIC ACID; CHITOSAN; HYALURONIC ACID; NICORANDIL; PECTIN;

ARTICLE; CARDIOVASCULAR DISEASE; DRUG SOLUBILITY; INFRARED SPECTROSCOPY; MATRIX TABLET; SUSTAINED DRUG RELEASE; TABLET DISINTEGRATION; TABLET FRIABILITY; TABLET THICKNESS;

ADULT; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG CARRIERS; FEMALE; HARDNESS; HUMANS; INTESTINAL ABSORPTION; KINETICS; MALE; NICORANDIL; POLYMERS; SOLUBILITY; SOLUTIONS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TABLETS; VASODILATOR AGENTS; WAXES;

EID: 48149113652     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.01.011     Document Type: Article

References (32)

1. Sweetman S.C. Martindale: The Complete Drug Reference. 34th ed. (2005), The Pharmaceutical Press, London (Electronic version)
2. Jin Y., Ohkuma H., Wang H., Natsume H., Sugibayashi K., and Morimoto Y. Fast-disintegration oral tablets having sustained release property. Yakugaku Zasshi 122 11 (2002) 989-994
3. Frydman A. Pharmacokinetic profile of nicorandil in humans: an overview. J. Cardiovasc. Pharmacol. 20 (1992) 34-44
4. Liew C.V., Chan L.W., Ching A.L., and Heng P.W. Evaluation of sodium alginate as drug release modifier in matrix tablets. Int. J. Pharm. 309 1-2 (2006) 25-37
5. Miyazaki Y., Tanaka Y., Yakou S., and Takayama K. In vivo drug release from hydrophilic dextran tablets capable of forming polyion complex. J. Control. Release 114 1 (2006) 47-52
6. Varshosaz J., Tavakoli N., and Kheirolahi F. Use of hydrophilic natural gums in formulation of sustained-release matrix tablets of tramadol hydrochloride. AAPS PharmSciTech 7 1 (2006) E24
7. Foda N.H., El-laithy H.M., and Tadros M.I. Implantable biodegradable sponges: effect of interpolymer complex formation of chitosan with gelatin on the release behavior of tramadol hydrochloride. Drug Dev. Ind. Pharm. 33 (2007) 7-17
8. Park S.H., Chun M.K., and Choi H.K. Preparation of an extended-release matrix tablet using chitosan/Carbopol interpolymer complex. Int. J. Pharm. 347 1-2 (2008) 39-44
9. Tapia C., Escobar Z., Costa E., Sapag-Hagar J., Valenzuela F., Basualto C., Gai M.N., and Yazdani-Pedram M. Comparative studies on polyelectrolyte complexes and mixtures of chitosan-alginate and chitosan-carrageenan as prolonged diltiazem clorhydrate release systems. Eur. J. Pharm. Biopharm. 57 (2004) 65-75
10. Fukuda M., Peppas N.A., and McGinity J.W. Properties of sustained release hot-melt extruded tablets containing chitosan and xanthan gum. Int. J. Pharm. 310 (2006) 90-100
11. Reddy K.R., Mutalik S., and Reddy S. Once-daily sustained-release matrix tablets of nicorandil: formulation and in vitro evaluation. AAPS PharmSciTech 4 (2003) 1-9 (Article (61))
12. Corti G., Cirri M., Maestrelli F., Mennini N., and Mura P. Sustained-release matrix tablets of metformin hydrochloride in combination with triacetyl-beta-cyclodextrin. Eur. J. Pharm. Biopharm. 68 2 (2008) 303-309
13. Gu X., Fediuk D.J., Simons F.E., and Simons K.J. Evaluation and comparison of five matrix excipients for the controlled release of acrivastine and pseudoephedrine. Drug Dev. Ind. Pharm. 30 (2004) 1009-1017
14. Thomsen L.J., Schaefer T., Sonnergaard J.M., and Kristensen H.G. Prolonged release matrix pellets prepared by melt pelletization. I. Process variables. Drug Dev. Ind. Pharm. 19 (1993) 867-1887
15. Adeyeye C.M., and Price J. Development and evaluation of sustained-release ibuprofen-wax microspheres. II. In vitro dissolution studies. Pharm. Res. 11 (1994) 575-579
16. Peri D., Bogdansky S., Allababidi S., and Shah J.C. Development of an implantable, biodegradable, controlled drug delivery system for local antibiotic therapy. Drug Dev. Ind. Pharm. 20 (1994) 1341-1352
17. The British Pharmacopoeia, British Pharmacopoeia Commission, HMSO, London, 2007 (Electronic version).
18. Cohen J.L., Hubert B.B., and Rhodes C.T. The development of USP dissolution and drug release standards. Pharm. Res. 7 (1990) 983-987
19. Korsmeyer R.W., Gurny R., Docler E., Buri P., and Peppas N.A. Mechanism of solute release from porous hydrophilic polymers. Int. J. Pharm. 15 (1983) 25-35
20. Ojha A., and Pargal A. Determination of nicorandil concentrations in human plasma using liquid chromatography. J. Pharm. Biol. Anal. 21 (1999) 175-178
21. Kristl J., Smid-Korbar J., Struc E., Schara M., and Rupprecht H. Hydrocolloids and gels of chitosan as drug carriers. J. Pharm. Biol. Anal. 99 (1993) 13-19
22. Efentakis M., and Buckton G. The effect of erosion and swelling on the dissolution of theophylline from low and high viscosity sodium alginate matrices. Pharm. Dev. Technol. 7 (2002) 69-77
23. Sriamornsak P., Thirawong N., Weerapol Y., Nunthanid J., and Sungthongjeen S. Swelling and erosion of pectin matrix tablets and their impact on drug release behavior. Eur. J. Pharm. Biopharm. 67 (2007) 211-219
24. Sriamornsak P., Thirawong N., and Korkerd K. Swelling, erosion and release behavior of alginate-based matrix tablets. Eur. J. Pharm. Biopharm. 66 (2007) 435-450
25. Bangudu A.B., and Pilpel N. Effects of interacting variables on the tensile strengths and disintegration times of paracetamol tablets. J. Pharm. Pharmacol. 37 (1985) 903-905
26. Macleod G.S., Fell J.T., and Collett J.H. An in vitro investigation into the potential for bimodal drug release from pectin/chitosan/HPMC-coated tablets. Int. J. Pharm. 188 (1999) 11-18
27. Peh K.K., and Yuen K.H. Development and in vitro evaluation of a novel multiparticulate matrix controlled release formulation of theophylline. Drug Dev. Ind. Pharm. 21 (1995) 1545-1555
28. Peh K.K., Wong C.F., and Yuen K.H. Possible mechanism for drug retardation from glyceryl monostearate matrix system. Drug Dev. Ind. Pharm. 26 (2000) 447-450
29. Siepmann J., and Peppas N.A. Modeling of drug release from delivery systems based on hydroxypropylmethylcellulose (HPMC). Adv. Drug Del. Rev. 48 (2001) 139-157
30. Tanaka N., Imai K., Okimoto K., Ueda S., Tokunaga Y., Ibuki R., Higaki K., and Kimura T. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): in vivo evaluation. J. Control. Release 112 (2006) 51-56
31. Kinoshita M., and Sakai K. Pharmacology and therapeutic effects of nicorandil. Card. Drug Ther. 4 (1990) 1075-1088
32. Kinoshita M., Nishikawa S., and Sawamura M. Comparative efficacy of high-dose versus low-dose nicorandil therapy for chronic stable angina pectoris. Am. J. Cardiol. 58 (1986) 733-738